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Abstract
Background: Diabetes prevalence is increasing globally, and Sub-Saharan Africa is no exception. With diverse
health challenges, health authorities in Sub-Saharan Africa and international donors need robust data on the
epidemiology and impact of diabetes in order to plan and prioritise their health programmes. This paper aims to
provide a comprehensive and up-to-date review of the epidemiological trends and public health implications of
diabetes in Sub-Saharan Africa.
Methods: We conducted a systematic literature review of papers published on diabetes in Sub-Saharan Africa
1999-March 2011, providing data on diabetes prevalence, outcomes (chronic complications, infections, and
mortality), access to diagnosis and care and economic impact.
Results: Type 2 diabetes accounts for well over 90% of diabetes in Sub-Saharan Africa, and population prevalence
proportions ranged from 1% in rural Uganda to 12% in urban Kenya. Reported type 1 diabetes prevalence was low and
ranged from 4 per 100,000 in Mozambique to 12 per 100,000 in Zambia. Gestational diabetes prevalence varied from
0% in Tanzania to 9% in Ethiopia. Proportions of patients with diabetic complications ranged from 7-63% for
retinopathy, 27-66% for neuropathy, and 10-83% for microalbuminuria. Diabetes is likely to increase the risk of several
important infections in the region, including tuberculosis, pneumonia and sepsis. Meanwhile, antiviral treatment for HIV
increases the risk of obesity and insulin resistance. Five-year mortality proportions of patients with diabetes varied from
4-57%. Screening studies identified high proportions (> 40%) with previously undiagnosed diabetes, and low levels of
adequate glucose control among previously diagnosed diabetics. Barriers to accessing diagnosis and treatment
included a lack of diagnostic tools and glucose monitoring equipment and high cost of diabetes treatment. The total
annual cost of diabetes in the region was estimated at US$67.03 billion, or US$8836 per diabetic patient.
Conclusion: Diabetes exerts a significant burden in the region, and this is expected to increase. Many diabetic
patients face significant challenges accessing diagnosis and treatment, which contributes to the high mortality and
prevalence of complications observed. The significant interactions between diabetes and important infectious
diseases highlight the need and opportunity for health planners to develop integrated responses to communicable
and non-communicable diseases.
Background
Sub-Saharan Africa, like the rest of the world, is experi-
encing an increasing prevalence of diabetes alongside
other non-communicable diseases [1]. In 2010 12.1 mil-
lion people were estimated to be living with diabetes in
Africa, and this is projected to increase to 23.9 million
by 2030 [2]. In Sub-Saharan Africa this trend is emer-
ging in a region grappling with high rates of communic-
able diseases - including the highest global prevalence of
HIV [3], Tuberculosis [4] and Malaria [5]. Diabetes is a
component cause of several other important and often
lethal diseases, both non-communicable diseases such as
cardiovascular disease [6] and renal disease [7], and
communicable diseases such as pneumonia [8], bacter-
aemia [9,10] and tuberculosis [11], which have consider-
able impacts on morbidity and mortality in the region
* Correspondence: victoriajhall@yahoo.co.uk
1Freelance Public Health Research Consultant, Private Practice, London, UK
Full list of author information is available at the end of the article
Hall et al. BMC Public Health 2011, 11:564
http://www.biomedcentral.com/1471-2458/11/564
© 2011 Hall et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.[12-17]. With this double burden of disease and limited
resources, diabetes must compete for political attention
and financial investment. With various regional and
international meetings and initiatives [18], including the
UN high-level meeting on Non-communicable Diseases
scheduled for 19-20 September 2011, diabetes and other
non-communicable diseases are beginning to get greater
political attention. Policymakers need guidance from
strong reviews of current information on trends and
public health impact. This review expands on recent
reviews of diabetes in the region [19-21], providing
greater consideration of the diabetes prevalence, access
to diabetes diagnosis and care, clinical outcomes follow-
ing diabetes (chronic diabetes complications, infections
and mortality), and economic costs.
Methods
We conducted a systematic review of all papers pub-
lished on diabetes in Sub-Saharan Africa between Janu-
ary 1999 and March 2011 and available on PubMed. We
defined Sub-Saharan Africa as all mainland African
countries south of the Sahara with the addition of the
island state of Madagascar. We searched for articles pro-
viding data from this region on diabetes prevalence, dia-
betes outcomes (chronic diabetes complications,
infections, and mortality), access to diabetes diagnosis
and care, and the economic burden caused by diabetes.
A combined keyword search on PubMed identified 1102
papers. See Additional File 1: Annex 1 for a description
of the review and Additional File 2: Annex 2 for the
keywords used. The references of included articles were
scanned to identify additional articles of interest pub-
lished before January 1999. Grey literature, from sources
including the websites of the World Bank, World Health
Organisation and International Diabetes Federation was
also reviewed.
Results
The prevalence of diabetes in Sub-Saharan Africa
Type 2 diabetes accounts for over 90% of diabetes cases
in Sub-Saharan Africa [19], whilst Type 1 diabetes,
gestational diabetes, and variant forms such as atypical
‘ketosis-prone’ diabetes and malnutrition-related dia-
betes constitute the remainder.
Type 2 diabetes
Just nine countries in the region have reported data
from type 2 diabetes (T2DM) prevalence surveys in the
last decade (see table 1) [22-36]. Two of these countries
have conducted population surveys with the assistance
of the World Health Organisation’s ‘STEPwise Approach
to Chronic Disease Surveillance Management’.P r e v a -
lence in the general population of T2DM recorded in
these studies ranged from 0.6% in rural Uganda [35] to
12% in urban Kenya [27]. A low to medium prevalence
(0-7%) was recorded in Cameroon, Ghana, Guinea,
Kenya, Nigeria, South Africa and Uganda and a very
high prevalence (> 10%) was recorded in Zimbabwe
(table 1).
Variation in prevalence recorded within countries was
common. Prevalence estimates varied considerably
between different studies for some countries, with esti-
mates for rural South Africa ranging from 3.9% [31] to
8.8% [33]. Variation between urban and rural popula-
tions was frequently observed, with a higher prevalence
recorded in urban populations [22,23,26,27,33,34]. Pre-
valence recorded in Christensen’s Kenyan survey ranged
from 2% in rural areas to 12% in urban areas [27].
One recent study investigated the incidence of type 2
diabetes in Kinshasa among a cohort of 807 people,
aged over 40 at baseline [37]. 93 participants developed
T2DM during the study period (December 2004 to Sep-
tember 2008), corresponding to an incidence rate of 29
(95% CI 15-43) per 1,000 person-years.
Type 1 diabetes
Four studies estimating the prevalence and/or incidence
of type 1 diabetes in the region were published since
1990 [38-41] (see table 2). Observed prevalence ranged
from 3.5 per 100,000 persons in Mozambique [40], to
12 per 100,000 persons in Zambia [40]. Recorded inci-
dence ranged from 1.5 per 100,000 persons per year in
Tanzania [41] to 2.1 per 100,000 persons per year in
Ethiopia [39].
Gestational diabetes mellitus
The literature review identified two studies on the pre-
valence of gestational diabetes in Sub-Saharan Africa
1999-present, one in Ethiopia [42] and one in South
Africa [43] (see table 3). Three other relatively recent
studies, published before January 1999, were identified
[44-46]. The range of prevalence recorded in these five
s t u d i e si sc o n s i d e r a b l e ,f r o m0 %a m o n gp r e g n a n t
women in Tanzania to 9% in Ethiopia.
Other Types of Diabetes
Several reviews describing diabetes trends in Africa
report the occurrence of other forms of diabetes, namely
’Atypical African diabetes’ or ’Ketosis-prone atypical dia-
betes mellitus’ and ’Malnutrition-related diabetes’ or
‘Tropical Diabetes’ [19,20,47]. However, beyond describ-
ing their existence and aetiology, no studies investigating
the population prevalence oft h e s ef o r m so fd i a b e t e si n
the region were identified.
Outcomes of diabetes
Diabetes mortality
Three studies investigated mortality in patients with dia-
betes in the region, two of which were conducted almost
twenty years ago (Table 4). These studies revealed high
mortality proportions, with 5-year mortality ranging
from 4% - 57% [48-50]. 41% of individuals with Insulin-
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Page 2 of 12Table 1 Prevalence of Type II Diabetes in cross sectional surveys in Sub-Saharan Africa 1999-2011
Country Author Site Sample size
(Participation rate
%)
Age
range
Method Prevalence (%) (95% CI) Un-diagnosed
diabetes (%)
Prevalence
IGT
(%) (95%
CI)
Prevalence
IFG
(%)
(95% CI)
% Obese
(BMI ≥30)
M F M+F Males Females
Cameroon Mbanya 1999
[22]
Urban
& Rural
Urban: 295 (> 90)
Rural: 384 (> 90)
24-74 OGTT/FBG (WHO
85, ADA 97)
Urban:
1.0*
(0.1-3.6)
Rural: 1.1*
(0.1-4.0)
Urban: 2.8*
(0.9-6.6)
Rural: 0.5*
(0-3.0)
Urban: 2.0*
Rural: 0.8*
- Urban (M:
1.6* (0.3-4.6)
F: 4.6*
(0.8-13))
Rural: (M: 6.4
(3.3-11.3)
F: 3.1*
(1.1-6.8))
--
Sobngwi
2002[23]
Urban
& Rural
Urban: 1183 (96)
Rural: 1282 (98)
≥15 FBG
(WHO 98)
Urban:
6.2*
(3.7-8.9)
Rural:
4.7*
(2.5-6.9)
Urban: 4.7*
(2.6-6.8)
Rural: 2.9*
(1.5-4.4)
- - - Urban: (M:
4.4 (2.6-4.3)
F: 10.4 (7.8-
13))
Rural: (M: 4.9
(2.4-7.4)
F: 4.7 (2.8-
6.6))
Urban:
5.4*
Rural:
0.5*
Urban:
17.1*
Rural:
3.0*
MOH
Cambod
2004 [24]
Urban 10,824 ≥15 OGTT 6.40* 5.70* 6.06* 80 - - 7.51* 21.25*
Ghana Amoah 2002
[25]
Urban 4733 (75) ≥25 OGTT
(WHO 98, ADA
97)
7.7* 5.5* 6.4* 69.9 10.7* 6.0* - -
Guinea Balde 2007
[26]
Urban
& Rural
1537 (77) ≥35 FBG
(WHO 99)
-- Urban: 6.7*
(5.1-8.3)
Rural: 5.3*
(3.6-7.0)
Urban: 59
Rural: 100
- Urban: 10.3
(8.3-12.3)
Rural: 17.7
(14.7-20.6)
--
Kenya Christensen
2009 [27]
Urban
& rural
Urban: 281 (98.2)
Rural: 1178 (98.2)
≥17 FBG/OGTT
(WHO 99)
Urban &
Rural: 4.5*
(2.0-10.2)
Urban & Rural:
4.2* (1.409.4)
Urban:
12.2*
(5.4-23.2)
Rural: 2.2*
(0.8-5.2)
Combined:
4.2*
(2.0-7.7)
Urban: 21
Rural: 48
Urban: 13.2*
(4.6-26.5)
Rural: 8.6*
(5.1-14.0)
Combined:
12.0*
(9.2-15.2)
-- -
Mathenge
2010 [28]
Urban
& Rural
Urban: 1437
Rural: 2959
≥50 RBG - - Urban: 10
Rural: 5
Urban: 23
Rural: 41
- - Urban: 20
Rural: 10
Nigeria Okesina 1999
[121]
Rural 500 > 40 FBG 2.6 --
Nyenwe 2003
[29]
Urban 502 (67.1) ≥40 OGTT (WHO 99) 9.1* 6.3* 7.9*4 1 - - - -
Oladapo 2010
[30]
Rural 2000 18-64 FBG 2.1 2.8 2.5 27 - - 3.9
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2Table 1 Prevalence of Type II Diabetes in cross sectional surveys in Sub-Saharan Africa 1999-2011 (Continued)
South
Africa
Erasmus 2001
[122]
Urban 374 (workers) > 20 OGTT - - 4.5*- -
Alberts 2005
[32]
Rural 2106 > 30 FBG - - 8.8 30 7.4
Motala 2008
[33]
Rural 1025 (78.9) > 15 OGTT
(WHO 98)
3.5* 3.9* 3.9* 84.8 4.8* 41.5* - -
Tanzania Aspray 2000
[34]
Urban
& Rural
Urban: 770
Rural: 928
> 15 FBG
(WHO 98)
Urban:
5.9*
Rural:
1.7*
Urban: 5.7*
Rural: 1.1*
- - - Urban: (M:
3.6* W:4.7*)
Rural: (M:
0.8*
W: 1.1*)
Urban:
7.3*
Rural:
0.2*
Urban:
19.8*
Rural:
4.2*
Uganda Maher 2010
[35]
Rural 6678 ≥13 RPG - - 0.6*
(0.4-0.7)
74 - - 0.5 3.9
Zimbabwe MOH STEPS
2005 [36]
Pop
Rep
3081 ≥25 FBG --1 0- M: 5.3 (3.3-8)
F: 5.2
(4.1-6.7)
- 3.9 10.4
Method: OGTT - Oral Glucose Tolerance Test, FBG - Fasting Blood Glucose Test, WHO 85/97/99: World Health Organisation 1985/98/99 diagnostic criteria, ADA97/04 American Diabetes Association 1997/2004
diagnostic criteria; RPG - Random Plasma Glucose Test for “probable diabetes” (>11mmol/l), RBG - Random Blood Glucose Test diabetes categorised as >11.1mmol/l; *age standardised; IGT: Impaired Glucose
Tolerance; IFG Impaired Fasting Glucose; Pop rep - sample representative of national population.
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2Dependent Diabetes Mellitus (IDDM) died within five
years in a study in Tanzania, and half of these deaths
were attributed to ketoacidosis [50]. Infection was
another important cause of mortality, accounting for
48% of deaths in indeterminate diabetes cases, 32% in
IDDM and 23% in Non-Insulin Dependent Diabetics
(NIDDM) in the Tanzanian survey [50].
The prevalence of chronic diabetes complications among
persons with diabetes
Twenty-three studies on the prevalence of chronic com-
plications of diabetes among persons with diabetes pub-
lished from 1999-2011 were reviewed (see table 5)
[51-74]. The recorded prevalence of retinopathy ranged
from 7% in Kenya [63], to 63% in South Africa [67],
neuropathy ranged from 27% in Cameroon [52] to 66%
in Sudan [54], and the prevalence of microalbuminuria
ranged from 10% in Tanzania [74] to 83% in Nigeria
[73]. Some national variation was suggested, with
recorded retinopathy rates ranging from 7% to 22% in
Kenya [63,64].
Important infections and diabetes
Whilst epidemiological studies outside Sub-Saharan
Africa have associated diabetes with infectious dis-
eases of great importance in this region (see Discus-
sion section), the literature review identified little
epidemiological data on this association in Sub-
Saharan Africa. A few smaller case-control studies
have suggested that the prevalence of urinary tract
infections is increased in diabetic patients in Sub-
Saharan Africa, as observed in developed coun-
tries [75]. Several reviews have described the frequent
occurrence of gangrene, infection and sepsis asso-
ciated with diabetic foot ulcer disease [76] and with
trauma to the hand (tropical diabetic hand syn-
drome) [77] in Sub-Saharan Africa.
Access to diabetes diagnosis and treatment
All of the type II prevalence surveys which recorded
proportions of previously undiagnosed diabetes among
participants who attended screening programmes found
very high levels (≥40%). Proportions exceeded 50% in
five surveys, and reached 100% in rural Guinea
[24-27,29,33].
Beran et al surveyed the availability of diagnostic test-
ing tools in a sample of healthcare settings in three
countries, and found that in Mozambique urine glucose
strips were available in just 18% of health facilities sur-
veyed, ketone testing strips in 8% and blood glucose
metres in 21%, whilst availability in Mali was 54%, 43%
and 13% and in Zambia 61%, 54%, 49% [40,78].
Low levels of adequate glucose control in diagnosed
diabetics were reported in several prevalence studies
[24,68]. Only 27% of diagnosed type 2 diabetics receiv-
ing treatment in the Cameroon study had adequately
controlled glucose levels [24]. Of 99 type 1 diabetics in
the Tanzanian survey, only one person achieved good
glucose control [68]. None of the 99 type 1 diabetics
had the ability to monitor their glucose levels at home,
and hospitals were unable to routinely do this [68]. A
regular supply of insulin was unaffordable for many dia-
betics, with one month’s insulin supply costing 19.6
days wages in Malawi [79] and 25% of the minimum
wage in Tanzania [80]. One Sudanese study found that
65% of a families’ annual household expenditure on
health was spent on caring for a diabetic child [81].
Beran and Yudkin found that state interventions affected
insulin price, reporting that an annual supply of insulin
cost 5% of GDP in Mozambique, where it was subsi-
dised by the government, whereas it cost 25% of GDP in
Mali without subsidies [78]. One study investigated
Insulin availability and reported that one of five
Table 2 Prevalence and Incidence of Type 1 diabetes in Sub-Saharan Africa 1990-2011
Country Author Sample Age Incidence per 100,000 persons (95% CI) Prevalence per 100,000 persons
Ethiopia Aleumu (2009) [39] 1029 - 2.1 (2.0 - 2.2) -
Mozambique Beran (2005) [40] - 0-19 - 3.5
Sudan Elamin (1992) [38] 42,981 7-14 - 9.5
Tanzania Swai (1993) [41] 86 0-19 1.5 (1.3 - 1.7) -
Zambia Beran (2005) [40] - 0-19 - 12
Table 3 Prevalence of Gestational Diabetes in Sub-Saharan Africa 1990-2011
Country Author Site Sample size Method Prevalence GDM among women giving birth (%) (95% CI)
Ethiopia Seyoum (1999) [42] Rural 890 OGTT 3.7 (2.5 - 4.9)
Ethiopia Hailu (1994) [44] Rural/Urban 567 OGTT 9.2
South Africa Mamabolo (2006) [43] Rural 262 OGTT 1.5
(0.4 - 3.8)
Tanzania Swai (1991) [45] Rural 189 OGTT 0
South Africa Ranchod (1991) [46] Urban 1721 OGTT 3.8
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regular insulin supply[40].
Economic Costs of Diabetes
Few studies were identified which investigated the cost
of diabetes in the region. Kiriga et al (2009) estimated
that the total economic cost (direct and indirect) of dia-
betes in the WHO’s Africa region in 2000 was Int$25.51
billion (US$67.03 billion), or Int$3363 (US$8836) per
person with diabetes per year [82] (numbers converted
from International dollars to their equivalent value in
US dollars [83]). Kiriga also estimated that the direct
cost of treating diabetes in 2000 ranged from Int$876
(US$2302) to Int$1220.6 (US$3207) per person.
One study into the cost of caring for children with T1DM
in Sudan found that the mean annual expenditure on dia-
betes care was US$283 per diabetic child, 36% of which was
spent on insulin [81]. A Tanzanian study estimated that in
1989-1990 the total cost of outpatient care for all diabetic
patients was US$2.7 million, of which insulin accounted for
two-thirds of the expenditure, and total in-patient cost was
US$1.25 million [84]. As diabetes care in Tanzania was pro-
vided free of charge to users this total cost of US$4 million
was paid from the government health budget and
accounted for 8% of the government’s total health expendi-
ture 1989-1990. A South African study investigated the cost
of hyperglycaemic emergency admissions in South Africa
over a two month period in 2005 and reported an average
cost R5309, equivalent to US$712, per admission [85].
Discussion
Prevalence of diabetes
Prevalence of type 2 diabetes
The prevalence of T2DM appears to have increased consid-
erably from that recorded in earlier (pre-1985) surveys
conducted in the region, which found the prevalence in
Sub-Saharan Africa was typically below 1%, with the excep-
tion of studies in South Africa (3.6%) [86] and the Ivory
Coast (5.7% (Zmirou, D. 1979 thesis, reported in McLarty
et al 1990 and Motala et al 2003)) [87,88]. However, many
of these early studies may have underestimated prevalence,
due to the use of low sensitivity screening methods and
non-standardised diagnostic criteria [33,89,90].
Impaired Glucose Tolerance (IGT) and Impaired Fast-
ing Glucose (IFG) are predictors of incident T2DM [91].
Thus, a high IGT prevalence alongside a low T2DM
prevalence may indicate the early stage of a diabetes epi-
demic [92]. IGT prevalence suggests that the T2DM
prevalence is likely to increase further in several coun-
tries in the region, including Cameroon, Ghana and
Guinea (Table 1)...
Preventing obesity and increasing level of physical
activity is important for reducing the onset of T2DM.
Eight T2DM surveys measured the prevalence of obesity
among participants, which ranged from 0.2% among
rural males in Tanzania [34] to 21% among females in
urban Cameroon [24]. The Ministry of Health study in
Cameroon reported that controlling obesity and over-
weight levels would reduce diabetes by 15% in males and
13% in females [24]. The comparatively higher prevalence
of T2DM recorded in urban areas was associated with a
higher prevalence of obesity among the urban samples
and a lower proportion reporting regular physical activity
[23,34]. The projections that by 2025 70% of Africans will
live in cities, with a regional annual urban growth rate of
4.5% [93], suggest that levels of obesity and T2DM dia-
betes will continue to rise in the region [19].
Prevalence of other types of diabetes
As there is very limited data available on other forms of
diabetes in the region it is difficult to describe trends.
Table 4 Diabetes mortality studies in Sub-Saharan Africa from 1990
Country Author (Year) Diabetes Types Sample
(loss to follow
up)
Mortality (%) Mortality causes
(deaths by cause/total deaths)
5
year
20
year
Ethiopia Lester (1992) [49] Type 1 431 4 37 -
South
Africa
Gill (2005)[48] Type 1 88 (39) - 33 Renal failure (9/21)
Hypoglycaemia (6/21)
Ketoacidosis (2/21)
Infection (2/21)
Undetermined (2/21)
Tanzania McLarty (1990)
[50]
IDDM
1 272 40.5 - Leading causes:
IDDM: 50% Ketoacidosis; NIDDM: 24% Cardiovascular & renal
disease;
Indeterminate: 48% infection.
NIDDM
2 825 19 -
Indeterminate
type
153 57 -
1IDDM: Insulin Dependent Diabetes Mellitus;
2NIDDM: Non Insulin Dependent Diabetes Mellitus.
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Complication Location Author (year) Sample Setting Type of diabetes Prevalence (%)
Neuropathy Cameroon Ndip (2006) [52] 300 Hospital inpatient and
outpatient clinics
N/A 27.3%
Nigeria Odusan (2008)
[53]
108 Hospital outpatient clinic Type 2 Cardiac Autonomic
Neuropathy:
34.2%
Sudan Ahmed (2000)
[54]
120 Hospital outpatient clinic Type 1 & 2 Cardiac Autonomic
Neuropathy: 40%
Peripheral: 66%
Foot ulcers Cameroon Ndip (2006) [52] 300 Hospital inpatient and
outpatient clinics
N/A 13%
Kengne (2010)
[55]
1841 Hospital inpatients N/A 13%
Nigeria Ogbera (2006)
[56]
1500 Hospital inpatients &
outpatient clinic
Mixed 9.5%
Tanzania Gulam-Abbas
(2002) [57]
627 Hospital inpatients Mixed 15%
Retinopathy Botswana Mengesha (2006)
[58]
401 Outpatient clinics Mixed 9.2%
Cameroon Sobgnwi (1999)
[59]
64 Hospital outpatient clinic Mixed, non-proteinuric 37.5%
Ethiopia Seyoum (2001)
[60]
340 Hospital outpatient clinic Type 1 & 2 37.8%
Ghana &
Nigeria
Rotimi (2003) [61] 840 Hospital outpatient clinics Type 2 17.9%
Nigeria Omolase 2010
[62]
100 Hospital outpatient clinic Mixed 15%
Kenya Mwendwa (2005)
[63]
100 Hospital outpatient clinic Type 2 7%
Kenya Mwale (2007) [64] 96 Hospital outpatient clinic Type 2 22%
South Africa Motala (2001) [65] T1: 47
T2: 172
Hospital outpatient clinic Type 1 & 2 Type 1: 53.2%,
Type 2: 64.5%
South Africa Read & Cook
(2007) [66]
248 Hospital outpatient clinic Type 2 32.3%
South Africa Mash (2007) [67] 400 Outpatient clinics Mixed 63%
Tanzania Majaliwa (2007)
[68]
99 Hospital outpatient clinic Type 1 22.68%
Nigeria Unuigbe (2001)
124
66 Hospital outpatient clinic Type 1 & 2 23%
Microalbuminuria Cameroon Sobgnwi (1999)
[59]
63 Hospital outpatient clinic Mixed, non-proteinuric 53.1%
Ghana Eghan (2007) [71] 109 Hospital outpatient clinic Mixed 43.1%
Kenya Wanjohi (2002)
[51]
100 Hospital outpatient clinic Type 2 Albuminuria: 26%
Kenya Mwendwa (2005)
[63]
100 Hospital outpatient clinic Type 2 25%
Nigeria Unuigbe (2001)
[69]
66 Hospital outpatient clinic Type 1 & 2 50%
Nigeria Agaba (2004) [72] 65 Hospital outpatient clinic Type 2 49.2%
Nigeria Adetunji (2006)
[73]
50 Hospital outpatient clinic Type 2 > 5 yrs, non-
proteinuric
83%
Tanzania Lutale (2007) [74] T1: 91
T2: 153
Hospital outpatient clinic Mixed Type 1: 12%,
Type 2: 9.8%
Tanzania Majaliwa (2007)
[68]
99 Hospital outpatient clinic Type 1 29.3%
Coronary Heart
Disease
South Africa Kalk (2007) [70] 744 Hospital outpatient clinic Type 2 White: 23%,
Black: 4%
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dies, it is not clear whether the very low incidence rates
of T1DM of 1-2 per 100,000 are reliable. All the existing
studies based their estimates on previously diagnosed
cases rather than population screening, and misdiagnosis
and high community mortality may leave many cases
unknown [20,39,68]. This is supported by the observa-
tion that T1DM was often first diagnosed when patients
presented at healthcare facilities with acute diabetic
complications [48,85]. Similarly, more studies measuring
the prevalence of gestational diabetes are needed to
determine whether the observed variation from 0 to 9%
among pregnant women reflects true regional variation.
Outcomes of diabetes
Mortality and chronic complications
The three studies investigating mortality following dia-
betes found high proportions, and these may have been
underestimates or overestimates due to sampling only
selected diagnosed diabetic patients accessing healthcare.
More large-scale population-based studies are needed to
explore whether the varying diabetes complication pro-
portions in different countries reflect true variation.
Small samples sizes and hospital-based recruitment limit
the generalisability of these studies.
The observed high mortality in patients with diabetes
and high prevalence of diabetes complications is likely
to be a consequence of many late diagnosed and poorly
controlled cases. Assessing the public health importance
of diabetes demands an appreciation of the impact of
diabetes on other diseases and population mortality, and
in particular the benefits of well-controlled diabetes for
averting costly cardiovascular and microvascular compli-
cations [7,94]. The total cost of these complications is
likely to far outweigh the cost of effective primary and
secondary prevention.
Infections
Potential associations between diabetes and important
communicable diseases in the region, particularly tuber-
culosis and HIV, further complicate the pattern of
increasing diabetes prevalence in Sub-Saharan Africa
and the challenges posed on resource-constrained health
systems. Newer studies primarily outside Sub-Saharan
Africa provide evidence on such associations.
A recent meta-analysis of thirteen studies found that
diabetes was associated with a 3.1 times elevated risk of
tuberculosis [11], and a systematic review of 9 studies
found that this increased risk varied from 1.5 to 7.8
[95]. Studies have suggested that 20% of smear-positive
tuberculosis in India and 25% of tuberculosis in Mexico
is attributable to diabetes [96,97]. The increased risk of
tuberculosis associated with diabetes may be largely
attributed to poor glycemic control [98,99]. Unfortu-
nately, proper epidemiological studies of the diabetes-
tuberculosis association from Africa are to our knowl-
edge missing [100].
Meanwhile, the high prevalence of HIV and the roll-
out of ART may increase the prevalence of diabetes risk
factors and consequently diabetes incidence. Antiretro-
viral therapy (ART) for HIV, and to a small extent, HIV
itself, is associated with an increased risk of developing
the metabolic syndrome, which predisposes individuals
to develop type 2 diabetes and cardiovascular disease
[101]. A range of metabolic changes have been asso-
ciated with ART, such as increased central obesity [101],
increased insulin resistance [102], lipodystophy [103],
and dislipidemia [104]. These changes have also been
associated, although to a much lesser extent, with
untreated HIV[102]. One review found that prevalence
of metabolic syndrome among patients on ART ranged
between 18 and 33% [105].
Evidence from other countries of the associations
between diabetes and a range of other severe infectious
diseases also deserves consideration. Type 2 diabetes is
associated with a 25-75% increased risk of pneumonia
and pneumococcal bacteremia leading to hospitalisation
[106-111], and longer duration of diabetes, diabetes
complications, and poor long-term glycemic control
increase the risk [108,112]. Diabetes increases the risk of
developing severe sepsis, with one study reporting a 2.5-
fold increased risk for hospitalization with sepsis in dia-
betic individuals compared to the general population
[110]. Patients with diabetes mellitus have a two to
three fold increased risk of bacteremia and sepsis origi-
nating from the urinary tract compared with those with-
out diabetes [113]. Among 11 patients newly admitted
with type 1 diabetes at a teaching hospital in Nigeria, 9
(82%) presented with urinary tract infection, malaria, or
recurrent boils [114]. Bacteremia risk due to hemolytic
streptococci and staphylococci is also increased two to
three-fold in patients with diabetes [115-117], and often
originates from wound infections, which are an impor-
tant health problem in the region [20].
Projections of future diabetes trends have not consid-
ered the potential impact of these associations which
could affect the future diabetes burden. Consideration of
the associations between diabetes and the other major
communicable diseases in the region has been notably
absent from the literature - both peer reviewed and grey
literature. It is vital that awareness of these associations
is promoted so that complementary and integrated pro-
grammes in these disease areas can be planned [118].
Access to diagnosis and treatment
The high rates of undiagnosed and uncontrolled dia-
betes recorded highlight the presence of significant bar-
riers to accessing diagnosis and treatment. The high
rates of undiagnosed diabetes suggest that existing
screening practices in the region are not effective. Given
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nostic tools it is also likely that screening for diabetes is
not routinely performed.
Several important challenges to accessing diagnosis
and treatment have been identified in the literature: the
high financial cost of treatment, particularly insulin; the
limited availability of diagnostic tools, treatment and
glucose monitoring equipment; and a low awareness of
diabetes among healthcare professionals which was
reported by some authors[40]. Other important barriers
may exist that have not yet been identified, as few stu-
dies have focused on this issue, and more information
on the comparative importance of these factors is neces-
sary to effectively target any interventions.
Economic Impacts of Diabetes
Diabetes is an expensive disease, especially when the
cost of complications, including the many diseases
where diabetes is an underlying causal factor, is consid-
ered. Kiriga’s study highlighted the vast expense of treat-
ing diabetes in the WHO’s African region; however the
cost of complications were excluded from the study, and
therefore this is a significant underestimate of total cost
of diabetes. Kiriga estimated that the direct cost of treat-
ing diabetes in 2000 ranged from Int$876 (US$ 2302) to
Int$1220.6 (US$3207) per person. Even at this level of
direct cost, there is a significant discrepancy between
the cost and available expenditure, as the International
Diabetes Federation (IDF) has estimated that in 2010
national funding for the healthcare of diabetics in Africa
is just US$111 per person, which already amounts to 7%
of national healthcare expenditure [119].
With limited national funding, individual patients and
their families may have to spend significant proportions
of their income on treatment for diabetes, a level of
expenditure that may not be sustainable or affordable.
The Sudanese study found that families spend an aver-
age of US$283 per year caring for their diabetic child,
which amounted to 65% of the family’s annual expendi-
ture on health. It is possible that in this scenario other
health needs are overlooked in order to devote over 50%
of annual health expenditure to the one member of the
family with diabetes.
The burden of T2DM is disproportionately borne by
people of working age [120], which is also the age-group
most profoundly affected by HIV in this region. Redu-
cing the economic activity of this group through disease
and disability affects both household and national
economies. Diabetes therefore not only imposes consid-
erable costs of treatment on f a m i l i e s ,i ta l s oh i n d e r s
their ability to pay for this treatment through the loss of
income of the diabetic member. At a national level an
increasing prevalence of diabetes among the economic-
ally active, and the high prevalence of diabetic
complications and low survival rates, will negatively
impact economic development, and in turn the health
budget.
Information on the cost of diabetes, including the cost
of the complications, is critical for policymakers to high-
light the importance of introducing early and cost effec-
tive interventions for both primary and secondary
prevention.
Conclusion
With increasing prevalence and interactions with other
diseases, including the major communicable diseases of
the region, diabetes is becoming a pressing public
health problem for Sub-Saharan Africa. If effective
interventions are implemented in the near-future it
may be possible to avert much of this burden, as pri-
mary prevention and treatment can reduce the inci-
dence of both diabetes and a range of related diseases
where diabetes is a causal factor. However, establishing
timely and effective integrated diabetes programmes in
the region requires a shift in current public health
priorities, and this requires a much better evidence
base - both to highlight the scale of the problem and
the areas for intervention. Below are a set of recom-
mendations for necessary action in order to address
some of the knowledge gaps identified in this article.
As identified in the WHO 2008-2013 Action Plan for
the Global Strategy on Noncommunicable Diseases,
these tasks require comprehensive efforts from multi-
ple stakeholders, including countries, international
organisations, academic institutions, civil society and
the private sector.
Recommendations
1. Countries, with the assistance from academic
institutions, should ensure that local diabetes preva-
lence and incidence data are collected, for example
through the recurring Demographic and Health Sur-
veys, to increase the availability of good information
on current epidemiological trends.
2. Academic institutions should collect regional and
country-specific data on mortality, morbidity, costs,
and access to diagnosis and care.
3. Under the leadership of intergovernmental agen-
cies such as the World Health Organization and the
World Bank, models should be developed to assess
the public health impact of diabetes in relation to
other important diseases, to enable informed priori-
tisation of available health funding at country level.
4. International agencies, civil society and the private
sector should join forces and use their expertise and
network to promote awareness of the interactions
between diabetes and key communicable diseases in
Sub-Saharan Africa, to inform the development of
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grammes and health policies.
5. International agencies and civil society should
establish peer-learning and experience-sharing dis-
cussion forums to promote development of feasible
and cost-effective strategies and solutions for man-
agement and control of diabetes in Sub-Saharan
Africa.
Additional material
Additional file 1: Annex 1: Flow Diagram of Studies Reviewed. This
is a flow diagram of the studies reviewed in this systematic review.
Additional file 2: Annex 2: Keyword search terms. This describes the
keywords used to perform the literature search.
Acknowledgements and Financial support
Department of Clinical Epidemiology is a member of the Danish Centre for
Strategic Research in Type 2 Diabetes (the Danish Research Council, grant
no. 09-075724 and 10-079102).
Author details
1Freelance Public Health Research Consultant, Private Practice, London, UK.
2Department of Clinical Epidemiology, Clinical Institute, Aarhus University
Hospital, DK-8200 Aarhus N, Denmark.
3Senior Economist, Global Stakeholder
Engagement, NovoNordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark.
4Programme Director, Global Stakeholder Engagement, NovoNordisk A/S,
Novo Allé, DK-2880 Bagsværd, Denmark.
Authors’ contributions
NL and OH conceived the study and wrote the analysis plan. VH conducted
the literature review and analysis and wrote the first draft manuscript. NL,
RWT and OH reviewed the draft manuscript, provided critical comments and
suggested additional analyses. VH finalised the manuscript which was
subsequently approved by all authors.
Competing interests
VH undertook this review as a consultant for Novo Nordisk A/S. NL and OH
are both employees of Novo Nordisk A/S.
Received: 6 November 2010 Accepted: 14 July 2011
Published: 14 July 2011
References
1. WHO: The Global Burden of Disease: 2004 Update World Health Organisation:
Geneva; 2004.
2. Sicree R, Shaw J, Zimmet : The Global Burden: Diabetes and Impaired
Glucose Tolerance. Diabetes Atlas, IDF. 4 edition. International Diabetes
Federation: Brussels; 2009.
3. UNAIDS: 2010 Report on the global AIDS epidemic. Geneva: UNAIDS;
2010.
4. World Health Organisation: WHO Global Tuberculosis Control Report
2010. WHO: Geneva; 2010.
5. World Health Organisation: World Malaria Report 2010. WHO: Geneva;
2010.
6. Saydah SH, et al: Age and the burden of death attributable to diabetes
in the United States. Am J Epidemiol 2002, 156(8):714-9.
7. Brown WV: Microvascular complications of diabetes mellitus: renal
protection accompanies cardiovascular protection. Am J Cardiol 2008,
102(12A):10L-13L.
8. Kornum JB, T R, Riis A, Lervang HH, Schønheyder HC, Sørensen HT:
Diabetes, glycemic control, and risk of hospitalization with pneumonia:
a population-based case-control study. Diabetes Care 2008, 31(8):1541-5.
9. Thomsen RW, H H, Lervang HH, Johnsen SP, Schønheyder HC, Sørensen HT:
Risk of community-acquired pneumococcal bacteremia in patients with
diabetes: a population-based case-control study. Diabetes Care 2004,
27(4):1143-7.
10. Thomsen RW, H H, Lervang HH, Johnsen SP, Schønheyder HC, Sørensen HT:
Diabetes mellitus as a risk and prognostic factor for community-
acquired bacteremia due to enterobacteria: a 10-year, population-based
study among adults. Clin Infect Dis 2005, 40(4):628-31.
11. Jeon CY, Murray MB: Diabetes mellitus increases the risk of active
tuberculosis: a systematic review of 13 observational studies. PLoS Med
2008, 5(7):e152.
12. Rudan I, et al: Epidemiology and etiology of childhood pneumonia. Bull
World Health Organ 2008, 86(5):408-16.
13. Seale AC, et al: Maternal and early onset neonatal bacterial sepsis:
burden and strategies for prevention in sub-Saharan Africa. Lancet Infect
Dis 2009, 9(7):428-38.
14. Mayanja BN, et al: Septicaemia in a population-based HIV clinical cohort
in rural Uganda, 1996-2007: incidence, aetiology, antimicrobial drug
resistance and impact of antiretroviral therapy. Trop Med Int Health
15(6):697-705.
15. Reddy EA, Shaw AV, Crump JA: Community-acquired bloodstream
infections in Africa: a systematic review and meta-analysis. Lancet Infect
Dis 10(6):417-32.
16. Steen TW, Aruwa JE, Hone NM: The epidemiology of adult lung disease in
Botswana. Int J Tuberc Lung Dis 2001, 5(8):775-82.
17. Lonnroth K, et al: Tuberculosis control and elimination 2010-50: cure,
care, and social development. Lancet 375(9728):1814-29.
18. World Health Organisation: 2008-2013 Action Plan for the Global Strategy
for the Prevention and Control of Noncommunicable Diseases. WHO,
Geneva; 2008.
19. Levitt NS: Diabetes in Africa: epidemiology, management and healthcare
challenges. Heart 2008, 94(11):1376-82.
20. Gill GV, et al: A sub-Saharan African perspective of diabetes. Diabetologia
2009, 52(1):8-16.
21. Mbanya JC, et al: Diabetes in sub-Saharan Africa. Lancet 2010,
375(9733):2254-66.
22. Mbanya JC, et al: Standardized comparison of glucose intolerance in
west African-origin populations of rural and urban Cameroon, Jamaica,
and Caribbean migrants to Britain. Diabetes Care 1999, 22(3):434-40.
23. Sobngwi E, et al: Physical activity and its relationship with obesity,
hypertension and diabetes in urban and rural Cameroon. Int J Obes Relat
Metab Disord 2002, 26(7):1009-16.
24. MOH: Cameroon Burden of Diabetes Project (Cambod): Baseline Survey
Report. Ministry of Health, Cameroon; 2004.
25. Amoah AG, Owusu SK, Adjei S: Diabetes in Ghana: a community based
prevalence study in Greater Accra. Diabetes Res Clin Pract 2002,
56(3):197-205.
26. Balde NM, et al: Diabetes and impaired fasting glucose in rural and
urban populations in Futa Jallon (Guinea): prevalence and associated
risk factors. Diabetes Metab 2007, 33(2):114-20.
27. Christensen DL, et al: Prevalence of glucose intolerance and associated
risk factors in rural and urban populations of different ethnic groups in
Kenya. Diabetes Res Clin Pract 2009, 84(3):303-10.
28. Mathenge W, Foster A, Kuper H: Urbanization, ethnicity and
cardiovascular risk in a population in transition in Nakuru, Kenya: a
population-based survey. BMC Public Health 10:569.
29. Nyenwe EA, et al: Type 2 diabetes in adult Nigerians: a study of its
prevalence and risk factors in Port Harcourt, Nigeria. Diabetes Res Clin
Pract 2003, 62(3):177-85.
30. Oladapo OO, et al: A prevalence of cardiometabolic risk factors among a
rural Yoruba south-western Nigerian population: a population-based
survey. Cardiovasc J Afr 21(1):26-31.
31. Erasmus RT, et al: Prevalence of diabetes mellitus and impaired glucose
tolerance in factory workers from Transkei, South Africa. S Afr Med J
2001, 91(2):157-60.
32. Alberts M, et al: Prevalence of cardiovascular diseases and associated risk
factors in a rural black population of South Africa. Eur J Cardiovasc Prev
Rehabil 2005, 12(4):347-54.
33. Motala AA, et al: Diabetes and other disorders of glycemia in a rural
South African community: prevalence and associated risk factors.
Diabetes Care 2008, 31(9):1783-8.
Hall et al. BMC Public Health 2011, 11:564
http://www.biomedcentral.com/1471-2458/11/564
Page 10 of 1234. Aspray TJ, et al: Rural and urban differences in diabetes prevalence in
Tanzania: the role of obesity, physical inactivity and urban living. Trans R
Soc Trop Med Hyg 2000, 94(6):637-44.
35. Maher D, et al: Distribution of hyperglycaemia and related cardiovascular
disease risk factors in low-income countries: a cross-sectional
population-based survey in rural Uganda. Int J Epidemiol 40(1):160-71.
36. MOH: National Survey: Zimbabwe Non-Communicable Disease Risk
Factors (ZiNCoDs). Preliminary Report. Ministry of Health and Child
Welfare, Zimbabwe; 2005.
37. Longo-Mbenza B, et al: Metabolic syndrome, aging, physical inactivity,
and incidence of type 2 diabetes in general African population. Diab
Vasc Dis Res 7(1):28-39.
38. Elamin A, Eltayeb B, Tuvemo T: High Incidence of Type I Diabetes Mellitus
in Sudanese children. Ann Saudi Med 1997, 17(4):478-480.
39. Alemu S, et al: Insulin-requiring diabetes in rural Ethiopia: should we
reopen the case for malnutrition-related diabetes? Diabetologia 2009,
52(9):1842-5.
40. Beran D, Yudkin JS, de Courten M: Access to care for patients with
insulin-requiring diabetes in developing countries: case studies of
Mozambique and Zambia. Diabetes Care 2005, 28(9):2136-40.
41. Swai AB, Lutale JL, McLarty DG: Prospective study of incidence of juvenile
diabetes mellitus over 10 years in Dar es Salaam, Tanzania. BMJ 1993,
306(6892):1570-2.
42. Seyoum B, et al: Prevalence of gestational diabetes mellitus in rural
pregnant mothers in northern Ethiopia. Diabetes Res Clin Pract 1999,
46(3):247-51.
43. Mamabolo RL, et al: Prevalence of gestational diabetes mellitus and the
effect of weight on measures of insulin secretion and insulin resistance
in third-trimester pregnant rural women residing in the Central Region
of Limpopo Province, South Africa. Diabet Med 2007, 24(3):233-9.
44. Hailu A, Kebede D: High-risk pregnancies in urban and rural communities
in central part of Ethiopia. East Afr Med J 1994, 71(10):661-6.
45. Swai AB, et al: No deterioration of oral glucose tolerance during
pregnancy in rural Tanzania. Diabet Med 1991, 8(3):254-7.
46. Ranchod HA, Vaughan JE, Jarvis P: Incidence of gestational diabetes at
Northdale Hospital, Pietermaritzburg. S Afr Med J 1991, 80(1):14-6.
47. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF: Diabetes in
Africans. Part 1: Epidemiology and clinical specificities. Diabetes and
Metabolism 2001, , 27: 628-634.
48. Gill GV, Huddle KR, Monkoe G: Long-term (20 years) outcome and
mortality of Type 1 diabetic patients in Soweto, South Africa. Diabet Med
2005, 22(12):1642-6.
49. Lester FT: Clinical features, complications and mortality in type 1 (insulin-
dependent) diabetic patients in Addis Ababa, Ethiopia, 1976-1990. QJ
Med 1992, 83(301):389-99.
50. McLarty DG, Kinabo L, Swai AB: Diabetes in tropical Africa: a prospective
study, 1981-7. II. Course and prognosis. BMJ 1990, 300(6732):1107-10.
51. Wanjohi FW, et al: Nephropathy in patients with recently diagnosed type
2 diabetes mellitus in black Africans. East Afr Med J 2002, 79(8):399-404.
52. Ndip EA, Tchakonte B, Mbanya JC: A study of the prevalence and risk
factors of foot problems in a population of diabetic patients in
cameroon. Int J Low Extrem Wounds 2006, 5(2):83-8.
53. Odusan O, Familoni OB, Raimi TH: Correlates of cardiac autonomic
neuropathy in Nigerian patients with type 2 diabetes mellitus. Afr J Med
Med Sci 2008, 37(4):315-20.
54. Ahmed AM, Hussein A, Ahmed NH: Diabetic autonomic neuropathy. Saudi
Med J 2000, 21(11):1034-7.
55. Kengne AP, et al: Admission trends over 8 years for diabetic foot
ulceration in a specialized diabetes unit in cameroon. Int J Low Extrem
Wounds 2009, 8(4):180-6.
56. Ogbera AO, et al: An assessment of the disease burden of foot ulcers in
patients with diabetes mellitus attending a teaching hospital in Lagos,
Nigeria. Int J Low Extrem Wounds 2006, 5(4):244-9.
57. Gulam-Abbas Z, et al: Clinical outcome of diabetes patients hospitalized
with foot ulcers, Dar es Salaam, Tanzania. Diabet Med 2002, 19(7):575-9.
58. Mengesha AY: Spectrum of eye disorders among diabetes mellitus
patients in Gaborone, Botswana. Trop Doct 2006, 36(2):109-11.
59. Sobngwi E, et al: Microalbuminuria and retinopathy in a diabetic
population of Cameroon. Diabetes Res Clin Pract 1999, 44(3):191-6.
60. Seyoum B, et al: Retinopathy in patients of Tikur Anbessa Hospital
diabetic clinic. Ethiop Med J 2001, 39(2):123-31.
61. Rotimi C, et al: Prevalence and determinants of diabetic retinopathy and
cataracts in West African type 2 diabetes patients. Ethn Dis 2003, 13(2
Suppl 2):S110-7.
62. Omolase CO, et al: Diabetic retinopathy in a Nigerian community.
Singapore Med J 51(1):56-9.
63. Mwendwa FM, et al: Risk factor profile and the occurrence of
microvascular complications in short-term type 2 diabetes mellitus at
Kenyatta National Hospital, Nairobi. East Afr Med J 2005, 82(12 Suppl):
S163-72.
64. Mwale C, Karimurio J, Njuguna M: Refractive errors in type 2 diabetic
patients. East Afr Med J 2007, 84(6):259-63.
65. Motala AA, et al: Microvascular complications in South African patients
with long-duration diabetes mellitus. S Afr Med J 2001, 91(11):987-92.
66. Read O, Cook C: Retinopathy in diabetic patients evaluated at a primary
care clinic in Cape Town. S Afr Med J 2007, 97(10):941-2, 944.
67. Mash B, et al: Screening for diabetic retinopathy in primary care with a
mobile fundal camera–evaluation of a South African pilot project. S Afr
Med J 2007, 97(12):1284-8.
68. Majaliwa ES, et al: Survey on acute and chronic complications in children
and adolescents with type 1 diabetes at Muhimbili National Hospital in
Dar es Salaam, Tanzania. Diabetes Care 2007, 30(9):2187-92.
69. Unuigbe EI, et al: Microalbuminuria and associated factors in newly
diagnosed diabetics. Niger Postgrad Med J 2001, 8(4):187-92.
70. Kalk WJ, Joffe BI: Differences in coronary heart disease prevalence and
risk factors in African and White patients with type 2 diabetes. Diabetes
Res Clin Pract 2007, 77(1):107-12.
71. Eghan BA Jr, Frempong MT, Adjei-Poku M: Prevalence and predictors of
microalbuminuria in patients with diabetes mellitus: a cross-sectional
observational study in Kumasi, Ghana. Ethn Dis 2007, 17(4):726-30.
72. Agaba EI, Agaba PA, Puepet FH: Prevalence of microalbuminuria in newly
diagnosed type 2 diabetic patients in Jos Nigeria. Afr J Med Med Sci 2004,
33(1):19-22.
73. Adetunji OR, et al: Microalbuminuria and clinical correlates in black
A f r i c a np a t i e n t sw i t ht y p e2d i a b e t e s .West Afr J Med 2006,
25(4):279-83.
74. Lutale JJ, et al: Microalbuminuria among Type 1 and Type 2 diabetic
patients of African origin in Dar Es Salaam, Tanzania. BMC Nephrol 2007,
8:2.
75. Makuyana D, et al: Asymptomatic bacteriuria among outpatients with
diabetes mellitus in an urban black population. Cent Afr J Med 2002,
48(7-8):78-82.
76. Abbas ZG, Archibald LK: Challenges for management of the diabetic foot
in Africa: doing more with less. Int Wound J 2007, 4(4):305-13.
77. Abbas ZG, Gill GV, Archibald LK: The epidemiology of diabetic limb sepsis:
an African perspective. Diabet Med 2002, 19(11):895-9.
78. Beran D, Yudkin JS: Looking beyond the issue of access to insulin: What
is needed for propoer Diabetes care in resource-poor settings. Diabetes
Atlas, IDF. 4 edition. International Diabetes Federation: Brussels; 2009.
79. Mendis S, et al: The availability and affordability of selected essential
medicines for chronic diseases in six low- and middle-income countries.
Bull World Health Organ 2007, 85(4):279-88.
80. Neuhann HF, et al: Diabetes care in Kilimanjaro region: clinical
presentation and problems of patients of the diabetes clinic at the
regional referral hospital-an inventory before structured intervention.
Diabet Med 2002, 19(6):509-13.
81. Elrayah H, et al: Economic burden on families of childhood type 1
diabetes in urban Sudan. Diabetes Res Clin Pract 2005, 70(2):159-65.
82. Kirigia JM, et al: Economic burden of diabetes mellitus in the WHO
African region. BMC Int Health Hum Rights 2009, 9:6.
83. International Monetary Fund: World Economic Outlook Database, April.
2009, [cited 2011 06/04/2011].
84. Chale SS, S A, Mujinja PGM, McLarty DG: Must diabetes be a fatal disease
in Africa? Study of costs of treatment. BMJ 1992, , 304: 1215-18.
85. Pepper DJ, et al: Hyperglycaemic emergency admissions to a secondary-
level hospital - an unnecessary financial burden. S Afr Med J 2007,
97(10):963-7.
86. Marine N, et al: Diabetes, hyperglycemia and glycosuria among Indians,
Malays and Africans (Bantu) in Cape Town, South Africa. Diabetes 1969,
18(12):840-57.
87. Motala AA, Omar MA, Pirie FJ: Diabetes in Africa. Epidemiology of type 1
and type 2 diabetes in Africa. J Cardiovasc Risk 2003, 10(2):77-83.
Hall et al. BMC Public Health 2011, 11:564
http://www.biomedcentral.com/1471-2458/11/564
Page 11 of 1288. McLarty DG, Pollitt C, Swai AB: Diabetes in Africa. Diabet Med 1990,
7(8):670-84.
89. Faeh D, et al: Prevalence, awareness and control of diabetes in the
Seychelles and relationship with excess body weight. BMC Public Health
2007, 7:163.
90. Levitt NS, et al: Application of the new ADA criteria for the diagnosis of
diabetes to population studies in sub-Saharan Africa. American diabetes
association. Diabet Med 2000, 17(5):381-5.
91. Shaw JE, et al: Impaired fasting glucose or impaired glucose tolerance.
What best predicts future diabetes in Mauritius? Diabetes Care 1999,
22(3):399-402.
92. Motala AA: Diabetes trends in Africa. Diabetes Metab Res Rev 2002,
18(Suppl 3):S14-20.
93. UN-HABITAT: State of the World’s Cities: Trends in Sub-Saharan Africa.
UN-HABITAT: Nairobi; 2004.
94. Holman RR, et al: 10-Year Follow-up of Intensive Glucose Control in Type
2 Diabetes. N Engl J Med 2008, 359(15):1577-1589.
95. Stevenson CR, et al: Diabetes and the risk of tuberculosis: a neglected
threat to public health? Chronic Illn 2007, 3(3):228-45.
96. Stevenson CR, et al: Diabetes and tuberculosis: the impact of the
diabetes epidemic on tuberculosis incidence. BMC Public Health 2007,
7:234.
97. Ponce-De-Leon A, et al: Tuberculosis and diabetes in southern Mexico.
Diabetes Care 2004, 27(7):1584-90.
98. Leung CC, et al: Diabetic control and risk of tuberculosis: a cohort study.
Am J Epidemiol 2008, 167(12):1486-94.
99. Pablos-Mendez A, Blustein J, Knirsch CA: The role of diabetes mellitus in
the higher prevalence of tuberculosis among Hispanics. Am J Public
Health 1997, 87(4):574-9.
100. Dooley KE, Chaisson RE: Tuberculosis and diabetes mellitus: convergence
of two epidemics. Lancet Infect Dis 2009, 9(12):737-46.
101. Young FCJ, Johnstone LK, Unwin NC: A review of co-morbifity between
infectious and chronic disease in Sub Saharan Africa: TB and Diabetes
Mellitus, HIV and Metabolic Syndrome. Globalization and Health 2009,
5(9).
102. Grinspoon SK: Metabolic syndrome and cardiovascular disease in
patients with human immunodeficiency virus. Am J Med 2005, 118(Suppl
2):23S-28S.
103. Mallon PW, Cooper DA, Carr A: HIV-associated lipodystrophy. HIV Med
2001, 2(3):166-73.
104. Lichtenstein KA, et al: Clinical assessment of HIV-associated lipodystrophy
in an ambulatory population. AIDS 2001, 15(11):1389-98.
105. Jevtovic DJ, et al: The metabolic syndrome, an epidemic among HIV-
infected patients on HAART. Biomed Pharmacother 2009, 63(5):337-42.
106. Benfield T, Jensen JS, Nordestgaard BG: Influence of diabetes and
hyperglycaemia on infectious disease hospitalisation and outcome.
Diabetologia 2007, 50(3):549-54.
107. Muller LM, et al: Increased risk of common infections in patients with
type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005, 41(3):281-8.
108. Kornum JB, et al: Diabetes, glycemic control, and risk of hospitalization
with pneumonia: a population-based case-control study. Diabetes Care
2008, 31(8):1541-5.
109. Jackson ML, et al: The burden of community-acquired pneumonia in
seniors: results of a population-based study. Clin Infect Dis 2004,
39(11):1642-50.
110. Shah BR, Hux JE: Quantifying the risk of infectious diseases for people
with diabetes. Diabetes Care 2003, 26(2):510-3.
111. O’Meara ES, et al: Hospitalization for pneumonia in the Cardiovascular
Health Study: incidence, mortality, and influence on longer-term
survival. J Am Geriatr Soc 2005, 53(7):1108-16.
112. Thomsen RW, et al: Risk of community-acquired pneumococcal
bacteremia in patients with diabetes: a population-based case-control
study. Diabetes Care 2004, 27(5):1143-7.
113. Thomsen RW, et al: Diabetes mellitus as a risk and prognostic factor for
community-acquired bacteremia due to enterobacteria: a 10-year,
population-based study among adults. Clin Infect Dis 2005, 40(4):628-31.
114. Adeleke SI, et al: Childhood diabetes mellitus in Kano, North West,
Nigeria. Niger J Med 2010, 19(2):145-7.
115. Factor SH, et al: Invasive group A streptococcal disease: risk factors for
adults. Emerg Infect Dis 2003, 9(8):970-7.
116. Jackson LA, et al: Risk factors for group B streptococcal disease in adults.
Ann Intern Med 1995, 123(6):415-20.
117. Laupland KB, Ross T, Gregson DB: Staphylococcus aureus bloodstream
infections: risk factors, outcomes, and the influence of methicillin
resistance in Calgary, Canada, 2000-2006. J Infect Dis 2008, 198(3):336-43.
118. Maher D, Smeeth L, Sekajugo J: Health transition in Africa: practical policy
proposals for primary care. Bull World Health Organ 88(12):943-8.
119. Zhang PZX, Brown JB, Vistisen D, Sicree RA, Shaw J, Nichols GA: Economic
Impact of Diabetes. Diabetes Atlas, IDF. 4 edition. International Diabetes
Federation: Brussels; 2009.
120. Bradshaw D, et al: Estimating the burden of disease attributable to
diabetes in South Africa in 2000. S Afr Med J 2007, 97(8 Pt 2):700-6.
121. Okesina AB, et al: Prevalence of some risk factors of coronary heart
disease in a rural Nigerian population. East Afr Med J 1999, 76(4):212-6.
122. Erasmus RT, et al: Assessment of glycaemic control in stable type 2 black
South African diabetics attending a peri-urban clinic. Postgrad Med J
1999, 75(888):603-6.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/11/564/prepub
doi:10.1186/1471-2458-11-564
Cite this article as: Hall et al.: Diabetes in Sub Saharan Africa 1999-2011:
Epidemiology and public health implications. a systematic review. BMC
Public Health 2011 11:564.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hall et al. BMC Public Health 2011, 11:564
http://www.biomedcentral.com/1471-2458/11/564
Page 12 of 12